What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of investigation include Lung cancer, Internal medicine, Surgery, Oncology and Chemotherapy.
The Lung cancer study combines topics in areas such as Cisplatin, Survival rate, Tolerability, Placebo and Carcinoma.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Gastroenterology.
His work focuses on many connections between Surgery and other disciplines, such as Urology, that overlap with his field of interest in Zoledronic acid.
Giorgio V. Scagliotti interconnects Cancer, Adenocarcinoma and Tivantinib in the investigation of issues within Oncology.
In his research on the topic of Chemotherapy, Chemotherapy regimen is strongly related with ERCC1.
His most cited work include:
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3017 citations)
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer (2559 citations)
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 (1575 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery.
His work is dedicated to discovering how Internal medicine, Gastroenterology are connected with Neutropenia and other disciplines.
As a part of the same scientific study, Giorgio V. Scagliotti usually deals with the Oncology, concentrating on Gemcitabine and frequently concerns with Vinorelbine.
His Lung cancer research is multidisciplinary, incorporating perspectives in Carboplatin, Cancer, Cancer research and Carcinoma.
His Chemotherapy research incorporates themes from Regimen, Randomized controlled trial, Stage, Non small cell and Radiation therapy.
His work deals with themes such as Adverse effect and Urology, which intersect with Surgery.
He most often published in these fields:
- Internal medicine (61.74%)
- Oncology (50.23%)
- Lung cancer (47.89%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (61.74%)
- Oncology (50.23%)
- Lung cancer (47.89%)
In recent papers he was focusing on the following fields of study:
Giorgio V. Scagliotti mainly investigates Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer research.
Giorgio V. Scagliotti combines subjects such as Gastroenterology and Placebo with his study of Internal medicine.
Giorgio V. Scagliotti has included themes like Adverse effect and Neutropenia in his Placebo study.
His Oncology research includes elements of Cancer, Docetaxel, Surgery, Phases of clinical research and Hazard ratio.
His studies deal with areas such as Clinical trial, Disease, MEDLINE and Intensive care medicine as well as Lung cancer.
His studies in Chemotherapy integrate themes in fields like Nausea, Regimen, Colorectal cancer and Ceritinib.
Between 2015 and 2021, his most popular works were:
- Lung cancer: current therapies and new targeted treatments (821 citations)
- Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial (238 citations)
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (217 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Lung cancer, Oncology, Disease and Prostate cancer.
As part of his studies on Internal medicine, Giorgio V. Scagliotti often connects relevant areas like Gastroenterology.
His work carried out in the field of Lung cancer brings together such families of science as Cancer, Targeted therapy, Clinical trial, Intensive care medicine and Radiation therapy.
His research integrates issues of Tivantinib, Phases of clinical research and Immunotherapy in his study of Oncology.
The study incorporates disciplines such as Precision medicine, Cisplatin, Quality of life, Allele frequency and Gene mutation in addition to Disease.
The concepts of his Prostate cancer study are interwoven with issues in Prospective cohort study, Medical physics, Disease management and Cancer staging.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
